China’s WuXi to build yet another biologics plant, this one with continuous manufacturing
Wednesday, 23 May 2018｜Source：CHINA CHAMBER OF COMMERCEFOR IMPORT&EXPORT OF MEDICINES &HEALTH PRODUCTS｜Author：
China’s WuXi Biologics is at it again, announcing plans for a third new manufacturing site in less than a month. The CDMO will build this new biologics manufacturing plant, its 10th, in Singapore and said this one will include continuous manufacturing capabilities.
The WuXi city-based CDMO said today that it will invest about $60 million to erect the facility, which will eventually employ 150. It will be its first Asian plant built outside of China. The company recently announced plans to build a plant in Ireland to serve the European markets.
The facility will include two 2,000-liter traditional fed-batch bioreactors and one 500-liter bioreactor with perfusion-based continuous processing capabilities. This facility will be able to handle both clinical and small-volume commercial production. An early-stage bioprocess development lab will also be included. The new manufacturing facility is getting some financial backing from the Singapore Economic Development Board.
"We are all very excited to initiate our first overseas Asian site in Singapore to enable local companies and expedite biologics development in Asia,” Chris Chen, Ph.D., CEO of WuXi Biologics, said in a statement. “We are committed to becoming the most comprehensive capability and technology platform in the global biologics industry to enable both local and global partners."
Source: Fierce Pharma
